A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial

BACKGROUND: Sorafenib is an oral multikinase inhibitor with antiangiogenic/antiproliferative activity. A randomized phase 2b screening trial in human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer demonstrated a significant improvement in progression-free survival (PFS) wh...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Baselga, José, Costa, Frederico, Gomez, Henry, Hudis, Clifford A, Rapoport, Bernardo, Roche, Henri, Schwartzberg, Lee S, Petrenciuc, Oana, Shan, Minghua, Gradishar, William J
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2013
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3724697/
https://ncbi.nlm.nih.gov/pubmed/23876062
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1745-6215-14-228
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados